Time to Buy Cellectis S.A. (CLLS) After Today’s Significant Increase?

March 14, 2018 - By Maria Brooks

The stock of Cellectis S.A. (NASDAQ:CLLS) is a huge mover today! The stock increased 11.50% or $3.64 during the last trading session, reaching $35.29. About 683,580 shares traded or 269.09% up from the average. Cellectis S.A. (NASDAQ:CLLS) has declined 17.09% since March 14, 2017 and is downtrending. It has underperformed by 33.79% the S&P500.
The move comes after 5 months positive chart setup for the $1.24 billion company. It was reported on Mar, 14 by Barchart.com. We have $37.41 PT which if reached, will make NASDAQ:CLLS worth $74.58 million more.

Analysts await Cellectis S.A. (NASDAQ:CLLS) to report earnings on May, 8. They expect $-0.67 earnings per share, down 19.64 % or $0.11 from last year’s $-0.56 per share. After $-0.76 actual earnings per share reported by Cellectis S.A. for the previous quarter, Wall Street now forecasts -11.84 % EPS growth.

Cellectis S.A. (NASDAQ:CLLS) Ratings Coverage

Among 7 analysts covering Cellectis (NASDAQ:CLLS), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. Cellectis had 13 analyst reports since April 5, 2016 according to SRatingsIntel. SunTrust maintained Cellectis S.A. (NASDAQ:CLLS) on Friday, October 6 with “Hold” rating. On Tuesday, April 5 the stock rating was initiated by Ladenburg Thalmann with “Buy”. The company was maintained on Wednesday, September 6 by Nomura. As per Tuesday, February 28, the company rating was initiated by Wells Fargo. Jefferies maintained Cellectis S.A. (NASDAQ:CLLS) rating on Friday, October 27. Jefferies has “Buy” rating and $47.0 target. The firm has “Buy” rating by Oppenheimer given on Wednesday, August 16. SunTrust downgraded the stock to “Hold” rating in Wednesday, September 6 report. The firm earned “Buy” rating on Monday, September 25 by Jefferies. The firm has “Buy” rating given on Friday, June 2 by Oppenheimer. The company was maintained on Tuesday, June 6 by Jefferies.

More important recent Cellectis S.A. (NASDAQ:CLLS) news were published by: Investorplace.com which released: “Juno Therapeutics Inc (JUNO): 3 Reasons to Be Bullish” on September 27, 2017, also Marketwatch.com published article titled: “Cellectis SA ADR”, Marketwatch.com published: “Biotech stocks surge on Gilead’s Kite Pharma acquisition” on August 28, 2017. More interesting news about Cellectis S.A. (NASDAQ:CLLS) was released by: Quotes.Wsj.com and their article: “Cellectis SA ADR CLLS (US: Nasdaq)” with publication date: March 21, 2015.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company has market cap of $1.24 billion. The firm operates through two divisions, Therapeutics and Plants. It currently has negative earnings. The Company’s lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia and CLL.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: